Pemtumomab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Pemtumomab?
Monoclonal antibody
Source Mouse
Target MUC1
Clinical data
Trade names Theragyn
Intraperitoneal
Identifiers
 YesY
None
Chemical data
 N (what is this?)  (verify)

Pemtumomab (trade name Theragyn) is a mouse monoclonal antibody used to treat cancer. The substance has affinity to various types of cancer, like ovarian cancer and peritoneal cancer, via the polymorphic epithelial mucin (PEM or MUC-1) and delivers the radioisotope Yttrium-90 into the tumour.[1] As of 2009, it is undergoing Phase III clinical trials.[2]

It has been granted orphan drug status in Europe.[3]

References[edit]

  1. ^ Oei, AL; Moreno, M; Verheijen, RH; Sweep, FC; Thomas, CM; Massuger, LF; Von Mensdorff-Pouilly, S (2008). "Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer". International Journal of Cancer. Journal International Du Cancer 123 (8): 1848–53. doi:10.1002/ijc.23725. PMID 18661524. 
  2. ^ ClinicalTrials.gov
  3. ^ Antisoma's Lead Product, Pemtumomab Granted European Orphan Drug Status